BACKGROUND: A small proportion of @entity1 with @entity14 ( @entity14 ) have @entity5 at the time of diagnosis. A subset of @entity5 @entity124 ( @entity2100 ) that is associated with @entity6756 silencing due to promoter methylation. In the current study, the authors investigated the proportion of @entity5 with @entity2100 in @entity1 with @entity14 ( @entity14 ) and the concordance in @entity2100 status among @entity5 in a given individual. In addition, the authors examined @entity6756 and @entity4311 expression and @entity6756 promoter methylation in SCRCs. METHODS: The current study included 77 @entity1 , with a combined total of 170 invasive SCRCs, who were identified from a database of 2884 @entity1 with @entity14 . Instability was determined by polymerase chain reaction (PCR) amplification using a set of five markers. Tumors that were unstable at two or more @entity2100 ( @entity2100 ); otherwise, they were considered @entity124 ( @entity124 ). Expression of @entity6756 and @entity4311 was determined by immunohistochemistry. Methylation of the @entity6756 gene promoter was determined by a methylation-specific PCR assay. Statistical comparisons were made using the chi-square test or the Student t test. RESULTS: Of the 77 @entity1 in the study, 21 (27%) had a family history of @entity4309 -related @entity5 , but none fulfilled the Amsterdam II criteria. Fifty-four of 170 @entity5 (32%) were found to be @entity2100 . @entity1 with @entity5 were older and more frequently female. All but 1 @entity5 lacked expression of @entity6756 (n = 44) or @entity4311 (n = 8), or both (n = 1). All @entity6756 -negative @entity5 , compared with only 3 @entity6756 -positive @entity5 , were methylated at the @entity6756 promoter. Most @entity1 (n = 67; 87%) had either all @entity5 (n = 48; 62%) or all @entity5 (n = 19; 25%); 10 @entity1 (13%) had both @entity124 and @entity5 . The observed @entity2100 / @entity124 distribution was significantly different from the distribution expected based on an assumption of independence (P < 0.0001). CONCLUSIONS: There is a strong concordance in @entity2100 / @entity124 status among @entity5 in the same individual. This finding suggests that the @entity5 in @entity1 with @entity14 develop along a preferred molecular pathway.

Evidence of a preferred molecular pathway in XXXX with synchronous @entity14 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity6756 :: ('4292', 'Gene') :: ['MLH1'] @entity124 :: ('MESH:D053842', 'Disease') :: ['microsatellite stable', 'MSS', 'microsatellite instability'] @entity4309 :: ('MESH:D003123', 'Disease') :: ['hereditary nonpolyposis colon carcinoma'] @entity5 :: ('MESH:D009369', 'Disease') :: ['MSS tumors', 'malignancy', 'MSI tumors', 'MSI tumor', 'sporadic CRCs display', 'tumors', 'synchronous tumors'] @entity4311 :: ('4436', 'Gene') :: ['MSH2'] @entity2100 :: ('MESH:D005600', 'Disease') :: ['MSI', 'markers were considered unstable'] @entity14 :: ('MESH:D015179', 'Disease') :: ['SCRC', 'CRC', 'colorectal carcinoma', 'synchronous colorectal carcinoma']
@entity1 :: (9606,Species) :: ['patients']
